Founded in 2020, Piramal Pharma Limited, a flagship entity of the Piramal Group, is a dynamic player in the pharmaceutical landscape, delivering an array of products and services across both domestic and global markets.
With an extensive global footprint, the company boasts a network of 15 cutting-edge manufacturing facilities and a robust distribution network spanning more than 100 countries.
Piramal Pharma encompasses three pivotal divisions:
- Piramal Pharma Solutions (PPS): This integrated Contract Development and Manufacturing Organization (CDMO) operates on a global scale. It is dedicated to developing and manufacturing comprehensive solutions for innovator and generic companies across the entire drug life cycle. PPS leverages a globally interconnected network of facilities.
- Piramal Critical Care (PCC): PCC is a significant player in the Complex Hospital Generics sector. Its diverse product portfolio includes inhalation anesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anesthetics, injectable anti-infectives, and other vital therapies.
- India Consumer Healthcare (ICH) Business: This division specializes in selling over-the-counter products designed to cater to the healthcare needs of consumers in India.
Itsmultifaceted divisions, remains at the forefront of pharmaceutical innovation and delivery, consistently meeting the needs of a global clientele.
Piramal Pharma Limited Stock Quote #
- Open: ₹99.90
- High – Low: ₹100.35 – ₹98.00
- Previous Close: ₹99.55
- Total Traded Value: 21,41,193
- 52 Weeks High: ₹196.08 (Oct 19, 2022)
- 52 Weeks Low: ₹61.86 (Mar 28, 2023)
- Updated On: Aug 11, 2023 4:00 PM
Piramal Pharma Rights Issue 2023 Detail #
| Issue Open | Aug 8, 2023 – Aug 17, 2023 |
| Security Name | Piramal Pharma Limited |
| Issue Size (Shares) | 129,629,630 |
| Issue Size (Amount) | ₹1,050.00 Crores |
| Issue Price | ₹81 per share |
| Face Value | ₹10 per share |
| Listing At | BSE, NSE |
| Terms of Payment | The full amount of Rs. 81 for rights equity shares has to be paid on application. |
| Entitlement | 5 Rights Equity Share(s) for every 46 fully paid-up Equity Shares held on Record Date |
Piramal Pharma Rights Issue 2023 Issue Timetable #
| Last Date to buy shares | Aug 1, 2023 |
| Record Date | Aug 2, 2023 |
| Credit of Rights Entitlements | |
| Bid/Offer Opens On | Aug 8, 2023 |
| Renunciation of Rights Entitlements | Aug 10, 2023 |
| Bid/Offer Closes On | Aug 17, 2023 |
| Deemed Date of Allotment | Aug 23, 2023 |
| Credit Date | Aug 24, 2023 |
| Listing Date | Aug 28, 2023 |
Company Financials #
| Period Ended | 31 Mar 2021 | 31 Mar 2022 | 31 Mar 2023 |
| Assets | 10,899.78 | 12,797.04 | 14,522.56 |
| Revenue | 6,479.01 | 6,834.90 | 7,306.66 |
| Profit After Tax | 835.03 | 375.96 | -186.46 |
| Net Worth | 5,076.75 | 6,069.94 | 5,968.45 |
| Reserves and Surplus | 4,488.62 | 5,290.69 | 5,181.79 |
| Total Borrowing | 2,910.19 | 4,023.28 | 5,504.77 |
Amount in ₹ Crore
Objects of the Issue: #
The company intends to utilize the net proceeds from the issue towards the funding of the following objects:
- Repayment or prepayment, in full or in part, of certain borrowings, and
- General corporate purposes.
Piramal Pharma Rights Issue 2023 Documents #
ompany Contact Information #
Piramal Pharma Limited
Ground Floor, Piramal Ananta,
Agastya Corporate Park, Kamani Junction,
LBS Marg, Kurla, Mumbai 400 070Phone: +91 22 3802 3000
Email: shareholders.ppl@piramal.com
Website: https://www.piramal.com/
Ground Floor, Piramal Ananta,
Agastya Corporate Park, Kamani Junction,
LBS Marg, Kurla, Mumbai 400 070Phone: +91 22 3802 3000
Email: shareholders.ppl@piramal.com
Website: https://www.piramal.com/
Piramal Pharma Rights Issue 2023 Registrar #
- Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: ppl.rights@linkintime.co.in
Website: https://linkintime.co.in/mipo/ipoallotment.html
